Just to clarify, my "what ever sticks" comment is
Post# of 148188
Other small biotechs adopt a plan of throwing out potential indications to try and milk out some value when the drug they have is not really that impressive. They are creating a lot of sizzle on the steak, because the steak is not that great.
It is tough to feel that these large number of huge indications are not a distraction from just focusing on HIV. However if the very real potential is there - why not? Especially since HIV is basically just waiting on the FDA.